SELLAS Life Sciences (SLS) Depreciation & Amortization (CF) (2010 - 2017)
SELLAS Life Sciences (SLS) reported Depreciation & Amortization (CF) of $25000.0 for Q3 2017, down 16.67% year-over-year from $30000.0 in Q3 2016, and little changed quarter-over-quarter from $25000.0 in Q2 2017.
SELLAS Life Sciences (SLS) Depreciation & Amortization (CF) (2010 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $25000.0 in Q3 2017.
- Depreciation & Amortization (CF) for Q3 2017 came in at $25000.0, down 16.67% year-over-year; the trailing twelve-month figure through Jun 2018 was $25000.0 (up 327.27% YoY), and the FY2016 annual result was $3000.0, down 97.2% from the prior year.
- Depreciation & Amortization (CF) steadied at $25000.0 in Q3 2017 per SLS's latest filing, from $25000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $232000.0 in Q1 2014 and troughed at -$254000.0 in Q4 2014.
- A 5-year average of $29368.4 and a median of $30000.0 in 2016 frame the typical range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 11500.0% in 2014 and fell as far as 315.25% in 2014.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $118000.0 in 2013, then slumped by 315.25% to -$254000.0 in 2014, then climbed by 22.44% to -$197000.0 in 2015, then soared by 53.3% to -$92000.0 in 2016, then surged by 127.17% to $25000.0 in 2017.
- Business Quant data shows SLS's Depreciation & Amortization (CF) at $25000.0 in Q3 2017, $25000.0 in Q2 2017, and $26000.0 in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 25,000.00 |
| Sep 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 25,000.00 |
| Jun 30, 2017 | 25,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Mar 31, 2017 | 26,000.00 |
| Dec 31, 2016 | -92,000.00 |
| Dec 31, 2016 | -92,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Sep 30, 2016 | 30,000.00 |
| Jun 30, 2016 | 59,000.00 |
| Jun 30, 2016 | 59,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Mar 31, 2016 | 6,000.00 |
| Dec 31, 2015 | -197,000.00 |
| Dec 31, 2015 | -197,000.00 |
| Sep 30, 2015 | 123,000.00 |
| Sep 30, 2015 | 123,000.00 |
| Jun 30, 2015 | 83,000.00 |
| Jun 30, 2015 | 83,000.00 |